Canny Clozel Gets Another $230m From J&J For Idorsia Hypertension Drug

 
• By Kevin Grogan

Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.

Gift box
A little extra: J&J is getting another drug developed in Actelion's labs • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas